YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the…
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery…
Pixium Vision announces FDA Breakthrough Device Designation for the Prima System in Dry AMD Pixium Vision to receive interactive communication…
Posts Strong Adjusted EBITDA Margin of 22% and Sequential Organic Growth of 2%CINCINNATI, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Quipt…
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation…
Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a…
Press Release Ecully, 28th of October, 2022 – 8:45 am Remarkable participation at 2022 Eurospine congress in Milan Spineway and…
Press Release Ecully, October 14, 2022 – 8 am Nine-month turnover of €5.4 million, up 82% Sales double in…